Meeting
2021 ASCO Annual Meeting
Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
Authors
Elizabeth R Kessler
University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO
Elizabeth R Kessler , Junxiao Hu , Geetika Srivastava , Douglas Jerome Kemme , Praveena Iruku , Vishal Rana , Steven Robert Schuster , Mali Amirault , Eryn Callihan , Thomas W. Flaig , Elaine Tat Lam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03149822
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4544)
DOI
10.1200/JCO.2021.39.15_suppl.4544
Abstract #
4544
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).
First Author: Dylan J Martini
Poster
2023 ASCO Annual Meeting
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
First Author: Bernard Doger de Spéville
Poster
2023 ASCO Annual Meeting
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.
First Author: Geoffrey Thomas Gibney
Poster
2023 ASCO Annual Meeting
CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).
First Author: Andrew Johns